Toxics of tobacco smoke and cardiovascular system: From functional to cellular damage

Current Pharmaceutical Design

Volumn 21, Issue 30, 2015, Pages 4370-4379

  Leone, Aurelio ^a,b  

^a Royal Society for Promotion of Hlth   (United Kingdom)

^b American Society of Hypertension   (United States)

Author keywords

Cell damage; Endothelium; Functional damage; Myocardium; Tobacco toxics

Indexed keywords

AROMATIC AMINE; CARBON MONOXIDE; NICOTINE; THIOCYANATE; TOBACCO SMOKE;

ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CELL DAMAGE; ENDOTHELIUM CELL; FUNCTIONAL STATUS; HEART FAILURE; HEART MUSCLE CELL; HUMAN; ISCHEMIC HEART DISEASE; PASSIVE SMOKING; PRIORITY JOURNAL; RECEPTOR BINDING; SMOKING; TOBACCO DEPENDENCE; TROPISM; ADVERSE EFFECTS; ANIMAL; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; PATHOLOGY; TOBACCO;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; SMOKING; TOBACCO;

EID: 84946047356     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150803145149     Document Type: Article

References (121)

1. Glantz SA, Parmley WW. Passive smoking and heart disease: mechanisms and risk. JAMA 1995; 273 (13): 1047-53.
2. Leone A. Passive smoking exposure and cardiovascular health. In: Jeorgensen NA, Ed. Passive Smoking and Health Research. New York: Nova Science Publishers, Inc., 2007; pp. 65-94.
3. He J, Vupputury S, Allen K, et al. Passive smoking and the risk of coronary heart disease-A meta-analysis of epidemiologic studies. N Engl J Med 1999; 340(12): 920-6.
4. Leone A, Landini L, Leone A. What is tobacco smoke? Sociocultural dimensions of the association with cardiovascular risk. Curr Pharm Des 2010; 16: 2510-7.
5. Rabinoff M, Caskey N, Rissling A, Park C. Pharmacological and chemical effects of cigarette additives. Am J Public Health 2007; 97(11): 1981-91.
6. Leone A, Giannini D, Bellotto C, Balbarini A. Passive smoking and coronary heart disease. Curr Vasc Pharmacol 2004; 2: 175-82.
7. Zevin S, Saunders S, Gourlay SG, Jacob P, Benowitz NL. Cardiovascular effects of carbon monoxide and cigarette smoking. J Am Coll Cardiol 2001; 38(6): 1633-8.
8. Sen S, Peltz C, Beard J, Zeno B. Recurrent carbon monoxide poisoning from cigarette smoking. Am J Med Sci 2010; 340(5): 427-8.
9. Leone A. Biochemical markers of cardiovascular damage from tobacco smoke. Curr Pharm Des 2005; 11: 2199-208.
10. Strachan DP, Jarvis MJ, Feyerabend C. Passive smoking, salivary cotinine concentrations and middle ear effusion in 7-year-old children. BMJ 1989; 289(6687): 1549-52.
11. Wayne M, Edwards PC, Borje S. Determination of nicotine in tobacco by molecularly imprinted solid phase extraction with differential pulsed elution. Anal Commun 1999; 36: 217-20.
12. Hummel T, Hummel C, Pauli E, Kobal G. Olfactory discrimination of nicotine-enantiomers by smokers and nonsmokers. Chem Senses 1992; 17: 13-21.
13. Leone A. Passive smoking, endothelial dysfunction and related markers in healthy individuals: an update. Curr Hypertens Rev 2012; 8: 141-50.
14. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease. An update. J Am Coll Cardiol 2004; 43(10): 1731-7.
15. Leone A. Relationship between cigarette smoking and other coronary risk factors in atherosclerosis: risk of cardiovascular disease and preventive measures. Curr Pharm Des 2003; 9: 2417-23.
16. Benowitz NL, Jacob P III, Jones RT, Rosemberg J. Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther 1982; 221: 368-72.
17. Hung J, Lam JYT, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432-6.
18. Castro de Souza EM, Silva MRE Jr.. The release of vasopressin by nicotine. Further studies on its site of action. J Physiol 1977; 265: 297-311.
19. Turner DM, Armitage AK, Briant RH, Dollery CT. Metabolism of nicotine by the isolated perfused dog lung. Xenobiotica 1975; 5: 539-51.
20. Leone A, Mori L, Bertanelli F, Fabiano P, Filippelli M. Indoor passive smoking: its effects on cardiac performance. Int J Cardiol 1991; 33: 247-52.
21. Wald NJ, Idle M, Boreham J, Bailey A. Carbon monoxide in breath in relation to smoking and carboxyhaemoglobin levels. Thorax 1981; 36: 366-9.
22. Leone A. Cardiovascular damage from smoking: a fact or belief? Int J Cardiol 1993; 38: 113-7.
23. Jaffe DA, Griffin D Ricker J. Analyzing cigarette smoke. Sci Teacher 1997; 64(9): 29-33.
24. Angelova M, Kolarova-Yaneva N, Nikolov A, Nedkova V. Smoking and thiocyanates in High School students, University students and children with hypertension. IOSR Journal Of Pharmacy(e)-ISSN: 2250-3013,(p)-ISSN: 2319-4219 Www.Iosrphr.Org Volume 4, Issue 1 (January 2014), Pp 56-61.
25. Leone A. How and why chemicals from tobacco smoke can induce a rise in blood pressure. World J Pharmacol 2012; 1(1): 10-20.
26. Maehly AC, Swensson A. Cyanide and thiocyanate levels in blood and urine of workers with low-grade exposure to cyanide. Int Arch Arbeitsmed 1970; 27: 195-209.
27. Cornelis MC, El-Sohemy A, Campos H. Genetic polymorphism of CY1A2 increases the risk of myocardial infarction. J Med Genet 2004; 41: 758-62.
28. Wald NJ, Hackshaw AK. Cigarette smoking: an epidemiological overview. Br Med Bull 1996; 52: 3-11.
29. McGill HC Jr.. The cardiovascular pathology of smoking. Am Heart J 1988; 115(1 Pat 2): 250-7.
30. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol 2014; 34(3): 509-15.
31. Auerbach O, Carter HW, Garfinkel L, Hammond EC. Cigarette smoking and coronary heart disease, a macroscopic and microscopic study. Chest 1976; 70: 697-705.
32. Pope III AC, Burnett RT, Thurston GD, et al. Cardiovascular mortality and long-term exposure to particulate air pollution. Circulation 2004; 109: 71-77.
33. Smith CJ, Fischer TH, Sears SB. Environmental tobacco smoke, cardiovascular disease, and the nonlinear dose-response hypothesis. Toxicol Sci 2000; 54: 462-72.
34. Meinert CL, Forman S, Jacobs DR, Stamler J. Cigarette smoking as a risk factor in men with a prior history of myocardial infarction. J Chronic Dis 1979; 32: 415-25.
35. Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276-82.
36. Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coronary spasm. Circulation 1993; 87: 76-9.
37. Leone A, Bertanelli F, Mori L, Fabiano P, Bertoncini G. Ventricular arrhythmias by passive smoke in patients with pre-existing myocardial infarction. J Am Coll Cardiol 1992; 3: 256A.
38. Cohn PF, Fox KM. Review Clinical cardiology: New frontiers. Silent myocardial ischemia. Circulation 2003; 108: 1263-77.
39. Leone A, Bertanelli F, Mori L, Fabiano P, Battaglia A. Features of ischaemic cardiac pathology from cigarette smoking. J Smok-Relat Dis 1994; 5: 109-14.
40. Leone A. Relation between coronary lesions and cigarette smoking of subjects deceased from acute myocardial infarction. A histopathological study. J Cardiobiol 2014; 2(2): 5.
41. Plank B, Kutyifa V, Moss AJ, et al. Smoking is associated with an increased risk of first and recurrent ventricular tachyarrhythmias in ischemic and nonischemic patients with mild heart failure: a MADIT substudy. Heart Rhythm 2014; 11(5): 822-7.
42. Zornoff LAM, Matsubara LS, Matsubara BB, et al. Beta-carotene supplementation attenuates cardiac remodeling induced by onemonth tobacco-smoke in rats. Toxicol Sci 2006: 90(1): 259-66.
43. Astrup P. Some physiological and pathological effects of moderate carbon monoxide exposure. BMJ 1972; 4: 447-52.
44. Lough J. Cardiomyopathy produced by cigarette smoke. Ultrastructural observations in guinea pigs. Arch Pathol Lab Med 1978; 102: 377-80.
45. Gvozdjakova A, Bada V, Sany L, et al. Smoke cardiomyopathy: disturbance of oxidative processes in myocardial mitochondria. Cardiovasc Res 1984; 18: 229-32.
46. Holman RL, McGill HC Jr., Strong JP, Geer JC. The natural history of atherosclerosis. The early aortic lesions as seen in New Orleans in the middle of the 20th century. Am J Path 1958; 34: 209-35.
47. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801-9.
48. Faggiotto A, Ross R, Harker L. Studies of hypercholesterolemia in the non-human primate: I. Changes that lead to fatty streak formation. Arterioscler 1984; 4: 323-40.
49. Hjermann I, Holme I, Velve Byre K, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease: Report from the Oslo Study Group of a Randomised Trial in Healthy Men. Lancet 1981; 318(8259): 1303-10.
50. Garrison RJ, Kannel WB, Feinleib M, et al. Cigarette smoking and HDL cholesterol the Framingham offspring study. Atheroscler 1978; 30(1): 17-25.
51. Davis J, Shelton L, Watanabe I, Arnold J. Passive smoking affects endothelium and platelets. Arch Intern Med 1989; 149: 386-9.
52. Levine PH. An acute effect of cigarette smoking on platelet function. A possible link between smoking and arterial thrombosis. Circulation 1973; 48: 619-23.
53. Pretorius E, Oberholzer HM, van der Spuy WJ, Meiring JH. Smoking and coagulation: the sticky fibrin phenomenon. Ultrastruct Pathol 2010; 34(4): 236-9.
54. Leone A. Smoking, haemostatic factors, and cardiovascular risk. Curr Pharm Des 2007; 13(16): 1661-7.
55. Kwiterovich PO Jr.. The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 1998; 82: 13Q-21.
56. Tall AR. An overview of reverse cholesterol transport. Eur Heart J 1998; 19: A31-5.
57. Cullen P, Schulte H, Assmann G. The Munster Heart Study (PROCAM). Total mortality in middle-aged men is increased at low total and LDL Cholesterol concentrations in smokers but not in nonsmokers. Circulation 1997; 96: 2128-36.
58. Sinzinger H, Kefalides A. Passive smoking severely decreases platelet sensitivity to antiaggregatory prostaglandins. Lancet 1982; 2: 392-3.
59. Burghuber OC, Punzengruper C, Sinzinger H, Haber P, Silberbauer K. Platelet sensitivity to prostacyclin in smokers and nonsmokers. Chest 1986; 90: 34-8.
60. Spach MS, Howell DA, Harris JS. Myocardial infarction and multiple thrombosis in a child with primary thrombocytosis. Pediatrics 1963; 31: 268-76.
61. Aird WC. Hemostasis and irreducible complexity. J Thromb Haemost 2003; 1: 227-30.
62. tenCate H, Aird WC. Lessons from venous thrombosis and disseminated intravascular coagulation: a synthesis of pathophysiological mechanisms of pro-thrombotic states. In: tenCate H, Levi M, Eds. Molecular Mechanisms of Disseminated Intravascular Coagulation. TX, USA: Landes Bioscience Publishers 2003.
63. Stec JJ, Silbershatz H, Tofler GH, et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham offspring population. Circulation 2000; 102: 1634-8.
64. Lowe GDO. Why do smokers have higher plasma fibrinogen levels than non-smokers? Clin Sci 2001; 101: 209-10.
65. Virchow RL. Beitr Z exp Pathol 1846; 2: 227-380.
66. Meade T, Imeson J, Sterling Y. Effects of changes in smoking and other characteristics in clotting factors and the risk of ischaemic heart disease. Lancet 1987; 2: 986-8.
67. Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991; 338: 1409-11.
68. Stone MC, Thorpe JM. Plasma-fibrinogen-a major coronary risk factor. JR Coll Gen Pract 1985; 35: 565-9.
69. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30(43): 10363-70.
70. Achneck HE, Sileshi B, Parikh A, et al. Pathophysiology of bleeding and clotting in the cardiac surgery patient. From vascular endothelium to circulatory assist device surface. Circulation 2010; 122: 2068-77.
71. Halpert B, Willms RK. Aneurysms of the aorta. An analysis of 249 necropsies. Arch Path 1962; 74: 163-8.
72. Stefanidis C, Vlachopoulos C, Tsiamis E. Unfavourable effects of passive smoking in aortic function in men. Ann Intern Med 1998; 128: 426-34.
73. Scollo MM, Winstanley MH, Eds., Tobacco in Australia. 3rd ed. Melbourne, Australia: Cancer Council Victoria 2008.
74. Buerger L. Thrombo-angiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene. Am J Med Sci 1908; 136: 567-80.
75. Joyce JW. Burger’s disease (thromboangiitis obliterans). Rheum Dis Clin North Am 1990; 16: 463-70.
76. Housley E. Treating claudication in five words. BMJ 1988; 296: 1483-4.
77. Kannel WB. Blood pressure as a cardiovascular risk factor: Prevention and treatment. JAMA 1996; 275: 1571-6.
78. Baer L, Radichevich I. Cigarette smoking in hypertensive patients. Blood pressure and endocrine response. Am J Med 1985; 78: 564-8.
79. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci 2006; 7: 335-46.
80. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77: 75-197.
81. Niedermaier ON, Smith ML, Beightol LA, et al. Influence of cigarette smoking on human autonomic function. Circulation 1993; 88(2): 562-71.
82. Shinozaki N, Yuasa T, Takata S. Cigarette smoking augments sympathetic nerve activity in patients with coronary heart disease. Int Heart J 2008; 49(3): 261-72.
83. Walker JF, Collins LC, Rowell PP, et al. The effect of smoking on energy expenditure and plasma catecholamine and nicotine levels during light physical activity. Nicotine Tob Res 1999; 1(4): 365-70.
84. Verdecchia P, Schillaci G, Borgioni C, et al. Cigarette smoking, ambulatory blood pressure and cardiac hypertrophy in essential hypertension. J Hypertens 1995; 13: 1209-15.
85. Tuomilehto J, Elo J, Nissinen A. Smoking among patients with malignant hypertension. BMJ 1982; 284: 1086.
86. Petitti DB, Klatsky AL. Malignant hypertension in women aged 15 to 44 years and its relation to cigarette smoking and oral contraceptives. Am J Cardiol 1983; 52: 297-8.
87. Powel JT. Vascular damage from smoking: disease mechanisms at the arterial wall. Vasc Med 1998; 3(1): 21-28.
88. Mikhailidis DP, Barradas MA, Nystrom ML, Jeremy JY. Cigarette smoking increases white blood cell aggregation in whole blood. J R Soc Med 1993; 86: 680-1.
89. Howard G, Burke GL, Szklo M, et al. Active and passive smoking are associated with increased carotid wall thickness. Arch Intern Med 1994; 154: 1277-82.
90. Leone A. Smoking and Hypertension: Independent or additive effects to determining cardiovascular damage. Curr Vasc Pharmacol 2011; 9: 585-93.
91. Tunstall-Pedoe H, Brown CA, Woodward M, Tavendale R, Passive smoking by self-report and serum cotinine and the prevalence of respiratory and coronary heart disease in the Scottish heart health study. J Epidemiol Commun Health 1995; 49(2): 139-43.
92. Steenland K. Passive smoking and the risk of heart disease. JAMA 1992; 267: 94-99.
93. Helsing K, Sandler D, Comstock G, Chee E. Heart disease mortality in nonsmokers living with smokers. Am J Epidemiol 1988; 127: 915-22.
94. Hole D, Gillis C, Chopra C, Hawthorne VM. Passive smoking and cardiorespiratory health in a general population in the west of Scotland. BMJ 1989; 299: 423-7.
95. Hirayama T. Passive smoking (Lett). NZ Med J 1990; 103: 54.
96. Lee PN, Chamberlain J, Alderson M. Relationship of passive smoking to risk of lung cancer and other smoking-associated diseases. Br J Cancer 1986; 54: 97-105.
97. Humble C, Croft J, Gerber A, et al. Passive smoking and 20-year cardiovascular disease mortality among nonsmoking wives, Evans County, Georgia. Am J Public Health 1990; 80: 599-601.
98. Howard G, Wagenknecht LE, Burke GL, et al. Cigarette smoking and progression of atherosclerosis: The atherosclerosis risk in communities (ARIC) study. JAMA 1998; 279: 119-24.
99. Salonen JT, Salonen R. Ultrasonography assessed carotid morphology and risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1991; 11: 1245-9.
100. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96: 1432-7.
101. Aronow WS. Effect of passive smoking on angina pectoris. N Engl J Med 1978; 299: 21-24.
102. Pimm PE, Silverman F, Shepard RJ. Physiological effects of acute passive exposure to cigarette smoke. Arch Environ Health 1978; 33: 201-13.
103. McMurray RG, Hicks LL, Thompson DL. The effects of passive inhalation of cigarette smoke on exercise performance. Eur J Appl Physiol 1985; 54: 196-200.
104. Allred EN, Blecher ER, Chaitman BR, et al. Short-term effects of carbon monoxide exposure on the exercise performance of subjects with coronary artery disease. N Engl J Med 1989; 321: 1426-32.
105. Sheps DS, Herbst MC, Hinderliter AL, et al. Production of arrhythmias by elevated carboxyhemoglobin in patients with coronary artery disease. Ann Intern Med 1990; 113: 343-51.
106. Celermajer DS, Adams MR, Clarkson P, et al. Passive smoking and impaired endothelium-dependent arterial dilation in healthy young adults. N Engl J Med 1996; 334: 150-4.
107. Durand MJ, Gutterman DD. Diversity in mechanisms of endothelium-dependent vasodilation in health and disease. Microcirculation 2013; 20(3): 239-47.
108. Hodgson JM, Marshall JJ. Direct vasoconstriction and endothelium-dependent vasodilation. Mechanisms of acetylcholine effects on coronary flow and arterial diameter in patients with nonstenotic coronary arteries. Circulation 1989; 79: 1043-51.
109. Giannini D, Leone A, DiBisceglie D, et al. The effects of acute passive smoke exposure on endothelium-dependent brachial artery dilation in healthy individuals. Angiology 2007; 58(2): 211-7.
110. Otsuka R, Watanabe H, Hirata K, et al. Acute effects of passive smoking on the coronary circulation in healthy young adults. JAMA 2001; 286: 436-41.
111. Pittilo MR. Cigarette smoking, endothelial injury and cardiovascular disease. Int J Exp Pathol 2000; 81(4): 219-30.
112. Michiels C. Physiological and pathological responses to hypoxia. Am J Pathol 2004; 164(6): 1875-82.
113. Roggendorf W, Neumann H, Thorn HL, Schneider H, Sarasa-Corral JL. Histologic examination of the rat after long-term exposure to subtoxic automotive exhaust gas. Arch Toxicol 1981; 47: 247-56.
114. Leone A, Landini L Jr, Biadi O, Balbarini A. Smoking and cardiovascular system: cellular features of the damage. Curr Pharm Des 2008; 14: 1771-7.
115. Bajusz E. The terminal electrolyte-shift mechanism in heart muscle; its significance in the pathogenesis and prevention of necrotizing cardiomyopathies. In Bajusz E, Ed, Electrolytes and Cardiovascular Diseases. Basel, SW: Karger 1965; Vol 1.
116. Bajusz E, Jasmin G. Observations on histochemical differentialdiagnosis between primary and secondary cardiomyopathies. Am Heart J 1965; 69: 83-92.
117. Tippets TS, Winden DR, Swensen AC, et al. Cigarette smoke increases cardiomyocyte ceramide accumulation and inhibits mitochondrial respiration. BMC Cardiovasc Disord 2014; 14 (1): 165.
118. Lewin NL, Bahram F, Rutqvist LE, Turesson I, Lewin F. Direct effects of pure nicotine, cigarette smoke extract, Swedish-type smokeless tobacco (Snus) extract and ethanol on human normal endothelial cells and fibroblasts. Anticancer Res 2011; 31: 1527-34.
119. Thomsen HK, Kjeldsen K. Threshold limit for carbon monoxideinduced myocardial damage. Arch Environ Health 1974; 29: 73-78.
120. Kjeldsen K, Thomsen HK, Astrup P. Effects of carbon monoxide on myocardium: ultrastructural changes in rabbits after moderate, chronic exposure. Circ Res 1974; 34: 339-48.
121. Ahmed S, Moschos CB, Lyons MM, et al. Cardiovascular effects of long-term cigarette smoking and nicotine administration. Am J Cardiol 1976; 37: 33-40.